Research Analysts Set Expectations for PRCT FY2025 Earnings

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) – Research analysts at William Blair lowered their FY2025 EPS estimates for shares of PROCEPT BioRobotics in a report released on Wednesday, November 5th. William Blair analyst B. Vazquez now expects that the company will post earnings per share of ($1.51) for the year, down from their prior forecast of ($1.49). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. William Blair also issued estimates for PROCEPT BioRobotics’ Q4 2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($1.01) EPS.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.56%. The firm had revenue of $83.33 million during the quarter, compared to analysts’ expectations of $80.78 million. During the same period in the previous year, the company earned ($0.40) earnings per share. PROCEPT BioRobotics’s quarterly revenue was up 42.6% compared to the same quarter last year. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS.

Other research analysts have also issued research reports about the company. Oppenheimer raised PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research report on Tuesday, September 2nd. Morgan Stanley lowered their target price on shares of PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $50.00 target price (down from $55.00) on shares of PROCEPT BioRobotics in a report on Wednesday. TD Cowen reduced their price target on shares of PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Leerink Partners reissued an “outperform” rating and set a $55.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $63.30.

PROCEPT BioRobotics Stock Down 1.0%

PRCT opened at $31.30 on Friday. PROCEPT BioRobotics has a one year low of $30.80 and a one year high of $103.81. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.86 and a current ratio of 9.21. The stock has a market capitalization of $1.74 billion, a P/E ratio of -20.46 and a beta of 0.98. The business’s 50-day simple moving average is $36.19 and its 200-day simple moving average is $47.81.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of hedge funds and other institutional investors have recently bought and sold shares of PRCT. ANTIPODES PARTNERS Ltd acquired a new position in PROCEPT BioRobotics in the 1st quarter valued at $30,000. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of PROCEPT BioRobotics in the 3rd quarter worth $30,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of PROCEPT BioRobotics in the first quarter valued at about $40,000. Vega Investment Solutions increased its stake in shares of PROCEPT BioRobotics by 52.0% during the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after acquiring an additional 265 shares during the period. Finally, CWM LLC increased its stake in shares of PROCEPT BioRobotics by 69.5% during the first quarter. CWM LLC now owns 873 shares of the company’s stock worth $51,000 after acquiring an additional 358 shares during the period. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).